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Abstract
Introduction To evaluate stereotactic body radiotherapy (SBRT) in low-risk Prostate Cancer patients as preferred treatment 
option in emergency health conditions.
Materials and methods From April 2013 to September 2015, 28 patients with low-risk prostate cancer were prospectively 
enrolled. The SBRT prescribed dose was 36.25 Gy in 5 fractions, twice a week. Primary endpoints were acute and late toxic-
ity. Secondary endpoints were biochemical recurrence free survival (bRFS) and overall survival.
Results Median follow-up was 65.5 months (range 52–81). No acute G3 or G4 toxicity was recorded. Acute G1 or G2 geni-
tourinary (GU) toxicity occurred in 43% and acute G1–G2 gastrointestinal (GI) toxicity in 14%. Late G1 and G3 GU toxicity 
in 18% and 3.5%, respectively. The G3 toxicity was not directly attributable to radiotherapy. Late G1 GI toxicity occurred 
in 18%. 5yy bRFS was 96.5% (95% CI 82.3–99.4%).
Conclusions Stereotactic body radiotherapy for early prostate cancer reported safe toxicity profile and a good clinical outcome 
at the median follow-up of 5 years. It may be an useful option if radiotherapy is required in emergency medical conditions.
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Introduction
The rapid development of Coronavirus Disease 2019 
(COVID-19) in the whole world led the WHO to declare 
on  11Th March 2020 a pandemic. In this situation, radiation 
oncologist are called to optimize the management of cancer 
patients that often are frail and cannot afford to postpone 
treatment [1]. Some preliminary suggestions have been indi-
cated, but there is still no clear consensus [2, 3]. However, 
the use of radiotherapic hypofractionation for some cancers 
seems to be shared worldwide.
Prostate cancer (PCa) is the second most common can-
cer in men with an estimated number of new diagnosis of 
164.700 in USA and 450.000 in Europe for 2018 [4, 5] and 
the majority of cases being diagnosed at early stage of dis-
ease [6]. Several treatments are available, and external beam 
radiotherapy (EBRT) is one of the first line options [7, 8].
In version 1 of 2020 NCCN Guidelines for Prostate Can-
cer, moderate hypofractionation regimens are indicated as 
preferred and several literature data demonstrate that, they 
are not inferior to standard fractionation (i.e. 74–81 Gy in 
37–45 fractions) [9]. So, several schedules on 20–28 frac-
tions (dose per fraction: 2.75–3 Gy) are widely adopted 
[10]. However, in the COVID-19 pandemic context, 20 frac-
tions seem also demanding for obvious reasons not only for 
patients but also for the radiation department. A possible 
alternative is ultra-hypofractionated courses (6.1–8 Gy per 
fraction up to 5–7 fractions) that, to date, are considered an 
appropriate regimen option across all risk groups of patients 
(from very low to high and very high risk) (NCCN 2020, v1) 
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[9]. It is well known that, in prostate cancer, radiation dose 
intensification correlates with better oncological outcomes 
and SBRT has shown acceptable efficacy and toxicity and 
has become “a” standard of care [11]. Despite the scientific 
evidence, SBRT has been exported and used only in large 
centers or in academic institutions but not taken into con-
sideration in other radiotherapy centers although they have 
Hi-Tech accelerators [12]. The main concern is related to the 
risk of inducing severe late toxicity in patients with a good 
prognosis [13]. Here, we report the long-term results of a 
phase II multicenter prospective trial on Stereotactic Body 
Radiotherapy in low-risk prostate cancer patients. In this 
paper, we suggest that SBRT can be cost-effective with mini-
mal toxicity and can therefore be offered more to patients, 
especially in emergency health conditions.
Materials and methods
The study was approved by the research Ethics Board 
(N. RITS. 13.001), registered on clinicaltrials.gov (NCT 
02423889) and conducted in accordance with the Declara-
tion of Helsinki and Good Clinical Practice guidelines. Writ-
ten, informed consent was obtained from all participants.
From April 2013 to September 2015, 28 of 30 planned 
patients were enrolled (17–61%, 5–18% and 6–21% at 
IRCCS Ospedale Policlinico San Martino in Genoa, ASST 
Spedali Civili in Brescia and A.O.U. Città della Salute e 
della Scienza in Turin, respectively).
Patient selection and treatment details
The eligibility criteria for enrollment were the follow-
ing: histologically confirmed prostate adenocarcinoma, 
age > 18 years, life expectancy > 10 years, low-risk group 
(according to 2013 NCCN classification), PSA ≤ 10 ng/mL, 
cT1-T2a, no nodal involvement, no distant metastasis, no 
concomitant ADT, no previous prostatectomy, good perfor-
mance status (ECOG < 2). Exclusion criteria were: interme-
diate, high, very high or advanced disease, nodal involve-
ment, distant metastasis, presence of inflammatory intestinal 
and autoimmune diseases in the acute phase, anticoagulant 
therapy in progress, hip replacement or other abdominal-
pelvic devices that make it impossible to acquire the images 
necessary for planning, previous pathology malignant 
neoplastic excluded basal cell skin cancer, previous pelvic 
radiotherapy and mental disease that cannot ensure a valid 
informed consent.
Patients were staged with an accurate anamnesis, clinical 
examination, rectal digital exploration (DRE), initial PSA 
and routine blood exams, pelvic multi-parametric magnetic 
resonance imaging (mp-MRI), chest computer tomography 
(CT), bone scan (although both chest CT and bone scan 
would not be required by NCCN guidelines), prostate biopsy 
with at least 6 fragments. Rectoscopy was performed only 
in case of suspected inflammatory diseases or intestinal 
diverticulosis.
A treatment planning CT scan was carried out from L1 to 
the proximal third of the femurs with 2.5 mm slices.
All patients were immobilized in the supine position 
with the arms on the chest using dedicated immobilization 
systems with a comfortable full bladder and empty rectum. 
Patients were instructed to drink 500 mL of water 30 min 
before CT scan and treatment. The SBRT prescribed dose 
was 36.25 Gy in 5 fractions, twice a week with a Biologi-
cally Effective Dose (BED) of 211 Gy. The clinical target 
volume (CTV) included the prostate, and a 5 mm mar-
gin was added to CTV to obtain the planning target vol-
ume (PTV). The CTV was countered using a deformable 
registration of T2 MRI sequences with the planning CT. 
Organs at risk (OARs) constraints were the following: V36 
Gy < 1 cc, V100 < 1.8 Gy, V90 < 3.6 Gy, V80 < 7.3 Gy, 
V50 < 18.25 Gy for rectum, V36Gy ≤ 1 cc, V37 ≤ 1 cc, 
V50 ≤ 40%, V100 ≤ 10% for bladder, V29.5 Gy < 50% for 
penile bulb, V20 ≤ 54% for femoral heads and ≤ 10% of pre-
scription dose for small and large bowel outside the PTV.
SBRT was delivered by Helical Tomotherapy Hi.Art 
(Genoa and Brescia) and Elekta Axesse (Turin) using 
VMAT with an integrated system of Image-Guided Radio-
therapy (IGRT). Daily IGRT setup verification and correc-
tion with Megavoltage CT (MVCT) with Tomotherapy or 
Cone Beam CT (CBCT) with Axesse was performed before 
each fraction. Planning optimal goals included for the PTV 
V95% > 98%, V103% < 3% and V105% < 0.5 cc and for the 
CTV V95% > 99%.
Follow‑up and toxicity assessment
Patients were assessed with clinical evaluations and PSA at 
1-month after RT, then every 3 months for the first year, then 
twice a year for the following four years and annually there-
after. The acute and late toxicity according to the CTCAE 
version 4.0 and RTOG/EORTC scale was recorded. The 
biochemical relapse was defined according to the American 
Society for Therapeutic Radiology and Oncology (ASTRO) 
definition (nadir + 2 ng/mL).
Endpoints
Primary endpoints were acute and late toxicity. Secondary 
endpoints were biochemical recurrence free survival (bRFS), 
and overall survival (OS). bRFS was calculated from the 
date of end of treatment and the date of the diagnosis of the 
biochemical recurrence; OS was calculated from the date of 
the end of treatment to the date of the patient’s death due 
to any cause.
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Statistical analysis
The planned sample size was 30 patients. Patient accrual 
was expected to be completed within September 2015, at 
that time the accrual was stopped. Demographic and tumor 
characteristics were summarized using mean, median and 
range for continuous variables and proportions for cat-
egorical variables. The PSA nadir was set to be the lowest 
PSA value following treatment completion. Kaplan–Meier 
method was used to estimate bRFS and OS and reported as 
probability of being event-free at 5 years, 95% confidence 
interval (95%CI). For these survival functions, patients alive 
and without events were censored at the time of last follow-
up. All analyses were conducted using SPSS Statistics v. 
22.0 2013 (IBM Corporation, New York, NY, USA).
Results
Patient’s baseline characteristics are shown in Table 1. 
Median follow-up was 65.5 months (range 52–81). All 
patients have a localized low-risk PCa with Gleason Score 
(GS) 3 + 3 = 6/10, PSA at diagnosis ≤ 10 (median 5.84 ng/
mL) and no one performed concomitant androgen-depriva-
tion therapy (ADT). The median age of patients was 72 years 
old (range 55–80).
According to the 2013 NCCN classification of low-risk 
category, pts without pelvic lymph node involvement and 
distant metastasis but with cancer also extended to both 
lobes (T2c) were included; currently, they are classified as 
favorable intermediate-risk class; so, according to the latest 
NCCN classification, we had: 15/28 patients (53%) very low 
risk, 10/28 patients (36%) low risk and 3/28 patients (11%) 
favorable intermediate risk. When indicated, active surveil-
lance was proposed but patients refused it.
Toxicity
None patient developed G3 or G4 acute toxicity, 12/28 
patients (43%) presented G1 or G2 genitourinary (GU) 
toxicity consisting in: an increase of frequency, urgency, 
dysuria that resolved within 1 month after the end of radio-
therapy. In some cases, a mild anti-inflammatory therapy 
was administrated. Only 4/28 patients (14%) presented acute 
G1-G2 gastrointestinal (GI) toxicity consisting of anal pain 
and diarrhea (3 G1 and 1 G2 toxicity, respectively).
In regard to late toxicity, 5/28 patients (18%) presented 
G1 GU toxicity urinary urgency and nycturia and only one 
patient had erectile dysfunction with minimal bleeding 
ejaculation, which afterwards resolved spontaneously in less 
than 3 months. One patient (3.5%) presented G3 GU toxic-
ity; this patient developed a second bladder tumor, treated 
firstly by TURV and then by TURP for an episode of uri-
nary retention with subsequent incontinence. In this case, 
probably the toxicity could not be attributed exclusively to 
radiation treatment. Concerning the late GI toxicity, only 
5/28 (18%) presented G1 toxicity with flatulence diarrhea.
Oncological outcomes
One patient developed a biochemical failure after 37 months 
from the end of SBRT. This patient, with a cT2aN0M0 dis-
ease stage and a PSA value of 8.49 ng/mL at diagnosis, 
was restaged with 18F- Choline PET/CT, which resulted 
negative and started ADT. 5yy bRFS was 96.5% (95% CI 
82.3–99.4%) (Fig. 1). Three out of 28 patients (11%) devel-
oped a second primary (2 bladder cancer and 1 pleural meso-
thelioma). At last follow-up, all patients were alive. None of 
them developed distant metastasis.
In regard to the PSA trend, the median PSA pre-RT 
value was 5.8 ng/mL, dropped down to 2.37 ng/mL after 
1 month then to 1.2 ng/mL at 3 months and below 1 ng/mL 
at 6 months. The median nadir PSA value was 0.25 ng/mL 
and was obtained after a median of 30 months from the end 
of the radiation treatment.
Discussion
In emergency medical situations, where the risk is that of 
not treating the patient with prostate cancer, delaying his 
therapy or initiating him with an inappropriate hormonal 
therapy, it is recommended to adopt radiotherapy schemes 
based on scientific evidence of efficacy, speed of execu-
tion and minimal toxicity [14]. Our analysis confirms that 
ultrahypofractionation schedule, as SBRT, in prostate cancer 
allows to obtain excellent result both in terms of acute and 
late toxicity and also in terms of oncological results. The 
literature data available to date have widely demonstrated 
Table 1  Patients characteristics
Numbers of pts (%)
Age









 Median (range) 5.84 (2.3–10)
Gleason score
 3 + 3 28 (100%)
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that, SBRT in these patients is not only feasible, but it is 
also a valid therapeutic choice and it is included as an option 
in any risk class groups (NCCN guidelines) [9]. A recent 
meta-analysis of 38 prospective studies (for a total of 6116 
patients in which the intermediate risk class was the most 
represented group), underlined this [15]. The acute toxic-
ity rates reported in this meta-analysis were very low with 
acute grade ≥ 3 toxicity ≤ 1% (acute G3 GU toxicity in 0.5% 
of patients, no G4 GU toxicity and acute G3 GI toxicity in 
0.06% of patients and G4 in 0.03%) and late ≥ G3 GU toxic-
ity of 2% and late G ≥ 3 GI toxicity of 1.1% [15]. Concerning 
the oncological outcomes, the reported overall 5-year bRFS 
rate was 95.3% (95% CI 91.3–97.5%), and 96.7% and 92.1% 
for the low and intermediate risk, respectively (bRFS is not 
available in patients at high risk because not all studies indi-
cated division by risk classes) [15, 16]. Even our results are 
completely comparable with the data reported.
In our opinion, SBRT in PCa is currently feasible in all 
centers equipped with hi-tech technology that includes daily 
IGRT, even outside a clinical trial. However, some literature 
data refer to patients treated with a 3DCRT technique, in 
particular the HYPO-RT-PC study (a randomized trial of 
78 Gy in 39 fractions versus 42.7 Gy in 7 fractions in inter-
mediate and high-risk patients) enrolled patients treated both 
with 3DCRT technique and with IMRT [17]. The prelimi-
nary data of the high-dose arm of RTOG 0126 trial showed 
a significant reduction of acute grade ≥ 2 GI and GU toxicity 
in patients treated with IMRT [18], data confirmed also by 
a recent meta-analysis both in regards severe acute toxicity 
and late GI toxicity [19, 20].
The limitations of this analysis are mainly represented by 
the sample size and by the fact that there have been enrolled 
patients that, to date, would be classified as very-low, low 
and intermediate favorable risk; however, the authors stress 
that this is attributable to the fact that the multicenter study 
started in 2013 when this type of treatment did not repre-
sent a solid option, as it can be now proposed, but rather an 
experimental treatment.
Moreover, the authors wanted to evaluate the long-term 
results before adopting the scheme as routine in the selected 
cases with early prostate carcinoma. It might be questionable 
the opportunity to plan a radical treatment in some of these 
patients (mainly those classified as very low and low risk) 
when a good alternative is represented by active surveillance 
or in which the treatment could be postponed [14]. In our 
experience, however, the patients have strongly chosen an 
active treatment and, in daily practice, the same patients ask 
for stereotactic technique. Even now, the demand for radia-
tion therapy by many males remains unchanged in the face 
of the desire to cure cancer.
In this moment of health emergency due to the COVID-
19 infection, it is clear that we are called to rethink and adapt 
our clinical practice [21]. Since the long-term results are 
satisfactory, this short fractionated radiotherapy should be 
strongly considered to reduce the access of patients to the 
radiotherapy department and subsequently reduce the risk 
of exposure for the patients (who are generally elderly) but 
also for the staff [22].
Conclusions
The indication for hypofractionation of radiation therapy is 
a recommendation to be adopted in emergency health condi-
tions for many cancers including prostate cancer. At date, the 
evidence of excellent long-term results obtained with SBRT 
for prostate cancer should advise other radiation oncologists 
to adopt this scheme to ensure effective and safe treatment 
even outside clinical trials.
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